Challenging Cases with Relapsed/Refractory FLT3+ Acute Myeloid Leukemia (AML)

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the complexities of relapsed refractory Acute Myeloid Leukemia (AML) with FLT3 mutations. Joined by leukemia specialists Dr. Uma Borate from the Ohio State University and Dr. Naval Daver from the MD Anderson Cancer Center, the discussion focused on real-life cases and the current standard of care for patients with FLT3-positive AML.

Key topics included:
•⁠  ⁠The importance of retesting for FLT3 mutations at the time of relapse
•⁠  ⁠Treatment paradigms for fit vs. unfit patients
•⁠  ⁠The role of Gilteritinib and combination therapies in relapsed settings
•⁠  ⁠Management of side effects, including cytopenias and differentiation syndrome
•⁠  ⁠Insights into the use of hypomethylating agents and the potential of oral therapies

Whether you're a healthcare professional or someone interested in the latest advancements in cancer care, this episode provides valuable insights into the management of challenging AML cases.

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

Don't forget to subscribe for more discussions on the latest in oncology!